Prefer to read instead? Read our micro-learning key clinical summary by clicking here.

This program is supported by an independent education grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

In this concise 20 minute teaching session, leading expert Enrico Novelli, MD explores practical strategies for early identification, monitoring, and management of cardiopulmonary, renal, and neurologic complications in adult SCD patients.

Accreditation: 0.25 AMA PRA Category 1 Credits™

Dr. Novelli traces the journey from a single β-globin mutation to the “cascade of four” processes that drive progressive organ damage. He explores how silent cerebrovascular, cardiopulmonary, and renal injuries emerge—and how timely surveillance can keep them in check. Learn about the latest emerging therapies, when to escalate to transfusion or RAAS blockade, and how multidisciplinary screening transforms life expectancy.

Session Highlights

• Connect genotype to phenotype: Understand the distinct risk profiles for stroke, pulmonary hypertension, and kidney disease.
• Spot trouble early: Apply evidence-backed protocols—annual TCD velocities, TRV-based echo intervals, and age-10 UACR checks—to detect organ dysfunction before symptoms appear.
• Translate science to bedside: Align hydroxyurea, transfusion, ACE/ARB therapy, and emerging combination regimens with each patient’s evolving risk landscape.

Who Should Watch

• Hematologists
• Primary-care and ER clinicians
• Pulmonologists
• Cardiologists
• Nephrologists
• Nurse Practitioners
• Physician Assistants
• Pharmacists
• Other healthcare professionals in SCD

Presented by

Enrico M. Novelli, MD, MS – Professor of Medicine; Division Chief, Classical Hematology, and Director, UPMC Adult Sickle Cell Disease Program. Dr Novelli’s NIH-funded research has clarified vascular dysfunction mechanisms and cognitive impairment in SCD, and he leads several multidisciplinary training grants.

Continuing Education Information

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Enrico Novelli has been a Consultant/Advisory Board Member for Novo Nordisk, Shield Therapeutics & Chiesi Pharmaceuticals.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.